| 抗肺动脉高压药物研究进展 |
| |
| 引用本文： | 梁宇,杜冠华. 抗肺动脉高压药物研究进展[J]. 中国药理学通报, 2019, 0(7): 902-906 |
| |
| 作者姓名： | 梁宇 杜冠华 |
| |
| 作者单位： | 1.中国医学科学院北京协和医学院药物研究所北京市药物靶点研究与新药筛选重点实验室 |
| |
| 基金项目： | 国家重点研发计划(No 2016YFC1000905);中国医学科学院医学与健康科技创新工程项目(No 2017-I2M-1-010) |
| |
| 摘 要： | 肺动脉高压是一种慢性心肺系统疾病,既可能是多种不明病因引起的原发性疾病,也可能是心肺功能异常相关疾病的并发症,其病理机制至今未明,病因复杂,死亡率高。目前临床上治疗药物有限,而且治疗效果差、不良反应多,急需疗效更好、更安全的药物。该文通过对文献调研和分析,总结以肺动脉高压和其他适应症为主的上市药物抗肺动脉高压的研究进展与作用缺陷,并提出抗肺动脉高压药物研发的问题,以期为今后肺动脉高压治疗药物的研究提供参考。
|
| 关 键 词： | 肺动脉高压 血管重构 预后 联合治疗 新适应症 药物进展 |
Progress in research of drugs for the treatment of pulmonary hypertension |
| |
| LIANG Yu,DU Guan-hua. Progress in research of drugs for the treatment of pulmonary hypertension[J]. Chinese Pharmacological Bulletin, 2019, 0(7): 902-906 |
| |
| Authors: | LIANG Yu DU Guan-hua |
| |
| Affiliation: | (Beijing Key Lab of Drug Target Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100050,China) |
| |
| Abstract: | Pulmonary hypertension is one of chronic cardiopulmonary diseases,which may not only be the primary disease caused by many unknown etiologies,but also the complication of diseases related to cardiovascular and pulmonary function abnormalities.Accompanied with high mortality and complex etiology,the mechanism of pulmonary hypertension is still unclear.At present,safe and effective drugs are necessary due to many adverse reactions of some drugs in clinical treatment and poor prognosis of patients.Here we discuss the progress and shortcomings of drugs indicated for PH and other diseases in the treatment of pulmonary hypertension.Moreover,we propose some problems that is to be solved regarding the research on anti-pulmonary hypertension drugs.This review summarizes current progress and provides reference for the future research on drugs for the treatment of pulmonary hypertension. |
| |
| Keywords: | pulmonary hypertension vascular remodeling prognosis combined therapy new indication drug development |
| 本文献已被 维普 等数据库收录！ |
|
